[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100555183":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":39,"centralContacts":44,"locations":51,"responsibleParty":118,"collaborators":49,"id":120,"slug":49,"hasResults":121,"nctId":122,"briefTitle":123,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":121,"sex":126,"minAge":49,"maxAge":49,"enrollmentInfo":127,"targetDuration":49,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":49,"overallStatus":54,"whyStopped":49,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":151},{"fullName":5,"class":6},"Miltenyi Biomedicine GmbH","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Long-term follow-up of CAR T cell therapy","EXPERIMENTAL","Assessment of long-term safety and efficacy of Miltenyi CAR T treatment.",[13,14,15],"Biological: MB-CART19.1","Biological: MB-CART20.1","Biological: MB-CART2019.1",[17,25,32],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"BIOLOGICAL","MB-CART19.1","Assessment of long-term safety and efficacy of MB-CART19.1 treatment.",[9],[23,24],"CD19-targeting CAR T cells","Anti-CD19 CAR T cells",{"type":18,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"MB-CART20.1","Assessment of long-term safety and efficacy of MB-CART20.1 treatment.",[9],[30,31],"CD20-targeting CAR T cells","Anti-CD20 CAR T cells",{"type":18,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"MB-CART2019.1","Assessment of long-term safety and efficacy of MB-CART2019.1 treatment.",[9],[37,38],"CD20\u002FCD19-targeting CAR T cells","Anti-CD20\u002FCD19 CAR T cells",[40],{"name":41,"affiliation":42,"role":43},"Claudia Rössig, Prof. Dr.","Universitätsklinikum Münster","PRINCIPAL_INVESTIGATOR",[45],{"name":46,"role":47,"phone":48,"phoneExt":49,"email":50},"Clinical Trial Manager","CONTACT","+4922048306820",null,"clinicaltrials.gov@miltenyi.com",[52,64,74,83,92,100,109],{"facility":53,"status":54,"city":55,"state":49,"zip":56,"country":57,"cosmosGeoPoint":58,"geoPoint":63,"contacts":49},"Charité Universitätsmedizin Berlin","RECRUITING","Berlin","13353","Germany",{"type":59,"coordinates":60},"Point",[61,62],13.41053,52.52437,{"lat":62,"lon":61},{"facility":65,"status":66,"city":67,"state":49,"zip":68,"country":57,"cosmosGeoPoint":69,"geoPoint":73,"contacts":49},"Universitätsklinikum Köln","ACTIVE_NOT_RECRUITING","Cologne","50937",{"type":59,"coordinates":70},[71,72],6.95,50.93333,{"lat":72,"lon":71},{"facility":75,"status":66,"city":76,"state":49,"zip":77,"country":57,"cosmosGeoPoint":78,"geoPoint":82,"contacts":49},"Uniklinikum Erlangen","Erlangen","91054",{"type":59,"coordinates":79},[80,81],11.00783,49.59099,{"lat":81,"lon":80},{"facility":84,"status":66,"city":85,"state":49,"zip":86,"country":57,"cosmosGeoPoint":87,"geoPoint":91,"contacts":49},"Universitätsmedizin Göttingen","Göttingen","37075",{"type":59,"coordinates":88},[89,90],9.93228,51.53443,{"lat":90,"lon":89},{"facility":42,"status":54,"city":93,"state":49,"zip":94,"country":57,"cosmosGeoPoint":95,"geoPoint":99,"contacts":49},"Münster","48149",{"type":59,"coordinates":96},[97,98],7.62571,51.96236,{"lat":98,"lon":97},{"facility":101,"status":66,"city":102,"state":49,"zip":103,"country":57,"cosmosGeoPoint":104,"geoPoint":108,"contacts":49},"Universitätsklinikum Tübingen","Tübingen","72076",{"type":59,"coordinates":105},[106,107],9.05222,48.52266,{"lat":107,"lon":106},{"facility":110,"status":66,"city":111,"state":49,"zip":112,"country":57,"cosmosGeoPoint":113,"geoPoint":117,"contacts":49},"Universitäts-Kinderklinik Würzburg","Würzburg","97080",{"type":59,"coordinates":114},[115,116],9.95121,49.79391,{"lat":116,"lon":115},{"type":119,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100555183",false,"NCT06508775","Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies","LONGSAFE","Inclusion Criteria:\n\n* Patient underwent treatment with a Miltenyi CAR T cell therapy in one of the parent trials at least 12 months prior to enrollment in long-term follow-up.\n* Patient has provided informed consent prior to enrollment.\n\nExclusion Criteria:\n\n* No exclusion criteria","ALL",{"count":128,"type":129},40,"ESTIMATED","INTERVENTIONAL",[132],"NA","The goal of this Long-Term Follow-Up Trial is to assess long-term safety and efficacy of Miltenyi CAR T treatment.",[135,136,137,138,139,140,141],"Melanoma Stage III","B-cell Non Hodgkin Lymphoma","Pediatric ALL","Childhood Non-Hodgkin Lymphoma","Acute Lymphatic Leukemia","Chronic Lymphatic Leukemia","Melanoma Stage IV","2025-11-20",{"date":144,"type":145},"2025-11-26","ACTUAL",{"date":147,"type":145},"2024-05-05",{"date":149,"type":129},"2040-12-31",{"name":5,"class":6},7]